tipifarnib has been researched along with lonafarnib in 38 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 224 | 34 | 90 |
| 309 | 92 | 94 | 6 | 0 | 3 |
| Protein | Taxonomy | tipifarnib (IC50) | lonafarnib (IC50) |
|---|---|---|---|
| Chain A, Protein farnesyltransferase alpha subunit | Rattus norvegicus (Norway rat) | 0.0019 | |
| Chain B, Protein farnesyltransferase beta subunit | Rattus norvegicus (Norway rat) | 0.0019 | |
| GTPase HRas | Homo sapiens (human) | 0.07 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.7 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Bos taurus (cattle) | 0.0083 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 0.1498 | |
| Protein farnesyltransferase subunit beta | Bos taurus (cattle) | 0.0083 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.1498 | |
| Protein farnesyltransferase subunit beta | Rattus norvegicus (Norway rat) | 0.0019 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Rattus norvegicus (Norway rat) | 0.0019 | |
| Geranylgeranyl transferase type-1 subunit beta | Bos taurus (cattle) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (78.95) | 29.6817 |
| 2010's | 6 (15.79) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, J; Curtin, ML; Florjancic, AS; Frost, DJ; Gu, WZ; Muchmore, SW; Sham, HL | 1 |
| Bauch, JL; Cohen, J; Gu, WZ; Hutchins, CW; Jakob, CG; Leonard, NM; Li, Q; Lin, NH; Marsh, K; Park, D; Rosenberg, SH; Sham, HL; Stoll, VS; Sullivan, G; Tong, Y; Wang, GT; Wang, L; Wang, X; Zhang, H | 1 |
| Bell, IM | 1 |
| Claiborne, A; Cohen, J; Frost, D; Gu, W; Hasvold, L; Hutchins, C; Jakob, CG; Li, Q; Li, T; Muchmore, S; Rosenberg, SH; Sham, HL; Stoll, VS | 1 |
| Claiborne, A; Cohen, J; Frost, D; Gu, WZ; Hutchins, C; Li, Q; Lin, NH; Rosenberg, SH; Sham, HL; Stoll, VS; Wang, W; Woods, KW | 1 |
| Bauer, KD; Bendale, P; Buckner, FS; Chakrabarti, D; Floyd, D; Gelb, MH; Hamilton, A; Hornéy, CP; Lombardo, LJ; Nallan, L; Pendyala, PR; Rivas, K; Sebti, S; Van Voorhis, WC; Weber, PC; Williams, DK; Windsor, WT; Yokoyama, K | 1 |
| Brunsveld, L; Gelb, MH; Hrycyna, CA; Michaelis, S; Tamanoi, F; Van Voorhis, WC; Waldmann, H | 1 |
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
| Distefano, MD; Ochocki, JD | 1 |
| Buuh, ZY; Lyu, Z; Wang, RE | 1 |
| Korzeniecki, C; Priefer, R | 1 |
| Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ | 1 |
| Bernhard, E; Hahn, SM; McKenna, WG | 1 |
| Adjei, AA; Dy, GK; Haluska, P | 1 |
| Dancey, JE | 1 |
| Caponigro, F | 1 |
| Adjei, AA; Dy, GK | 1 |
| Baum, C; Kirschmeier, P | 1 |
| Kelland, LR | 1 |
| Cortes, J | 1 |
| de Bono, JS; Rowinsky, EK; Tolcher, AW | 1 |
| Tauchi, T | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 1 |
| Helbig, G; Hołowiecki, J | 1 |
| Elhamri, M; Thomas, X | 1 |
| Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P | 1 |
| Feldman, EJ | 2 |
| Appels, NM; Beijnen, JH; Schellens, JH | 1 |
| Jiang, D; Zhang, M | 1 |
| Harousseau, JL | 1 |
| Berk, S; Gajewski, TF; Ho, AW; Kuna, T; Marks, RE; Robbel, C | 1 |
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Li, M; Liu, A; Liu, B; Luo, X; Yu, H; Zheng, H | 1 |
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
| Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF | 1 |
| Eşkazan, AE; Özgür Yurttaş, N | 1 |
| Cohen, J; Frost, D; Galicia, T; Gu, WZ; Hutchins, C; Li, Q; Li, T; Rosenberg, SH; Sham, HL; Stoll, VS; Woods, KW | 1 |
25 review(s) available for tipifarnib and lonafarnib
| Article | Year |
|---|---|
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Design; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms | 2004 |
Therapeutic intervention based on protein prenylation and associated modifications.
Topics: Animals; Antineoplastic Agents; Humans; Models, Molecular; Molecular Conformation; Progeria; Protein Prenylation; Proteins | 2006 |
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
Topics: Acetylation; Animals; Citrullination; Enzyme Inhibitors; Glycosylation; Humans; Methylation; Phosphorylation; Protein Prenylation; Protein Processing, Post-Translational; Proteins; Ubiquitination | 2018 |
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |
Current status of clinical trials of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction | 2001 |
Farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2001 |
Farnesyl transferase inhibitors as anticancer agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured | 2002 |
Agents targeting ras signaling pathway.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Benzodiazepines; Enzyme Inhibitors; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Imidazoles; MAP Kinase Kinase Kinases; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Piperidines; Proto-Oncogene Proteins c-raf; Pyridines; Quinolones; Signal Transduction | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Piperidines; Pyridines; Quinolones | 2003 |
Farnesyl transferase inhibitors in the treatment of breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2003 |
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Protein Prenylation; Proto-Oncogene Mas; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2003 |
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides | 2004 |
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2004 |
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction | 2004 |
[Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Topics: Alkyl and Aryl Transferases; Benzodiazepines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Myeloproliferative Disorders; Piperidines; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; ras Proteins; rho GTP-Binding Proteins | 2005 |
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins | 2005 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome | 2005 |
Development of farnesyl transferase inhibitors: a review.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2005 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
Farnesyltransferase inihibitors in hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Piperidines; Pyridines; Quinolones; Signal Transduction | 2007 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome | 2006 |
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones | 2013 |
Novel therapeutic approaches in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinolones; Recombinant Proteins | 2020 |
1 trial(s) available for tipifarnib and lonafarnib
| Article | Year |
|---|---|
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
13 other study(ies) available for tipifarnib and lonafarnib
| Article | Year |
|---|---|
Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Biological Availability; Biphenyl Compounds; Crystallography, X-Ray; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Half-Life; Imidazoles; Indicators and Reagents; Mice; Models, Molecular; Rats | 2003 |
Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Benzamides; Biological Availability; Cell Membrane Permeability; Crystallography, X-Ray; Dogs; Drug Design; Farnesyltranstransferase; Imidazoles; Models, Molecular; Molecular Structure; Nitriles; Structure-Activity Relationship | 2004 |
Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.
Topics: 4-Quinolones; Alkyl and Aryl Transferases; Crystallography, X-Ray; Farnesyltranstransferase; Models, Molecular; Pyridones; Quinolones; Structure-Activity Relationship | 2004 |
Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Cattle; Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Hydroxyquinolines; Indoles; Mice; NIH 3T3 Cells; Quinolones; Stereoisomerism | 2005 |
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
Topics: Alkyl and Aryl Transferases; Animals; Antimalarials; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Erythrocytes; Farnesyltranstransferase; Female; Humans; Malaria; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Plasmodium berghei; Plasmodium falciparum; Protein Prenylation; Quinolones; Rats; Structure-Activity Relationship | 2005 |
Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
Topics: | 2013 |
Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Pyridines; Quinolones | 2002 |
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperidines; Pyridines; Quinolones | 2003 |
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
Topics: Antibodies, Monoclonal; Blotting, Western; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; HSP40 Heat-Shock Proteins; Humans; Interferon-gamma; Interleukin-2; Interleukin-4; Lymphocyte Activation; MAP Kinase Kinase 4; Methionine; Phosphorylation; Piperidines; Protein Prenylation; Pyridines; Quinolones; Ribonuclease, Pancreatic; Ribosomal Protein S6 Kinases, 70-kDa; RNA Processing, Post-Transcriptional; T-Lymphocytes; Th1 Cells; Th2 Cells | 2007 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Mutation; Neuropeptides; Phosphorylation; Piperidines; Prenylation; Proteins; Pyridines; Quinolones; Ras Homolog Enriched in Brain Protein; Ribosomal Protein S6; RNA Interference; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Transfection | 2010 |
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |
Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.
Topics: Alkyl and Aryl Transferases; Animals; Benzimidazoles; Enzyme Inhibitors; Farnesyltranstransferase; Indoles; Mice; NIH 3T3 Cells; Quinolones | 2005 |